BVF, VRX - Valeant and Biovail Agree to Merge Combination Creates Leader in Specialty Pharmaceuticals Accretive to Stockholders of Both Companies in First 12 Months Combined Operating Cash Flow on a Trailing 12-Month Basis of $575 Million $175 Million in Annual Cost Synergies Fully Captured by Second Year Strong Cash Flow to Support Future Growth and to Strengthen Balance Sheet http://finance.yahoo.com/news/Valeant-and-Biovail-Agree-to-bw-414122136.html?x=0&.v=1